All Blogs
Jul 10, 2026
Top Obesity Drugs by Revenue in 2025: The Biggest Winners in the Weight Loss Market
Summary The obesity treatment market has shifted from a niche category to a major pharma growth engine, with revenues in the leading markets rising from about $16 billion in 2025 to a projected $80 billion by 2034 and potentially more than $100 billion by 2036. Eli Lilly led the category in 2025, driven by M...
Read More...
Jul 09, 2026
Presage Technologies Unveils Free Access to FDA-Cleared Contactless Vital Signs Technology; CliniComp Secures FDA Clearance for MIMPS PACS Viewer with Unified Imaging and AI Capabilities; Advita Ortho Strengthens the Scientific Foundation for Predictive Planning in Total Knee Arthroplasty; RunStar® Expands Health Device Portfolio with New Smart Blood Pressure Monitor; Nyra Medical Initiates ENHANCE Early Feasibility Study with First Patient Enrollment; Penumbra Enrolls First Patient in FORWARD Study for Distal Acute Ischemic Stroke
Presage Technologies Earned FDA Clearance for Contactless Vital Signs, Makes Them Available for Free On 07 July 2026, Presage Technologies announced that its SmartSpectra Vital Signs Monitor 1.0 SDK received U.S. FDA 510(k) clearance (K254169) for both iOS and Android platforms and made the FDA-cleared con...
Read More...
Jul 08, 2026
Decoding DNA, Redefining Dosage: How Pharmacogenomic Testing Services Are Rewriting the Rules of Modern Medicine
For decades, prescribing medicine has followed a "one-size-fits-all" playbook: a standard drug, a standard dose, and a hopeful wait to see how the patient responds. The pharmacogenomic testing service is quietly dismantling that model. By reading the genetic variants that govern how an individual absorbs, metaboliz...
Read More...
Jul 07, 2026
Novartis to Acquire Myricx Bio; Roche’s Divarasib Tops Approved KRAS G12C Inhibitors in Phase III NSCLC Trial; Otsuka Reports Positive Two-Year Phase 3 Results for VOYXACT in IgA Nephropathy; Revolution Medicines Reports Early Clinical Data for Zoldonrasib Combination Regimens at ESMO GI 2026; Can-Fite Completes Patient Enrolment for Interim Analysis in Pivotal Phase 3 Psoriasis Trial
Novartis to Acquire Myricx Bio to Expand Next-Generation ADC Portfolio Novartis has signed an agreement to acquire Myricx Bio, a privately owned biotechnology company based in the UK that is developing a novel class of antibody-drug conjugates (ADCs) featuring N-myristoyltransferase inhibitor (NMTi) payloads. ...
Read More...
Jul 06, 2026
Paragangliomas and Pheochromocytomas Treatment Space Steps into the Precision Therapy Era
Summary Pheochromocytoma and paraganglioma (PCPG/PPGL) are rare neuroendocrine tumors that arise from chromaffin cells and can occur in the adrenal glands or in extra-adrenal sites such as the thorax, abdomen, pelvis, bladder, and head and neck. Surgery remains the only curative option for localized disease,...
Read More...
Jul 03, 2026
The Future of Degenerative Disc Disease Treatment: Moving Beyond Symptom Relief with Cell Therapy
Summary In the US, chronic low back pain affects about 28% of the population, and DDD is estimated to account for roughly half of specific CLBP cases, or around 14 million diagnosed prevalent cases in 2025. Standard care includes pain relief, NSAIDs, physical therapy, lifestyle changes, injections, and surge...
Read More...
Jul 02, 2026
STARMED Secures FDA 510(k) Clearance for Benign Thyroid Nodule Ablation; SciBase Advances U.S. Expansion with FDA 510(k) Submission for Nevisense; ALR Technologies to Acquire CGM Medical Technology in US$45 Million and 200 Million Share Deal; Co-Diagnostics Completes Validation Studies Ahead of FDA 510(k) Submission for Upper Respiratory Point-of-Care Test; Corvention Launches Innovative Balloon Catheter in the U.S. Following First Clinical Case; OrthAlign Reports First Clinical Cases Using Lantern® ASC System
STARMED Received FDA 510(k) Clearance for a Benign Thyroid Nodule Ablation Indication On 01 July 2026, STARMED America announced that it had received FDA 510(k) clearance for the first radiofrequency ablation (RFA) system in the United States specifically indicated for the treatment of benign thyroid nodules. Th...
Read More...
Jul 01, 2026
DNA Diagnostics: Transforming Precision Medicine and Redefining Disease Detection
DNA diagnostics is no longer a niche laboratory technique reserved for research institutions, it has become one of the fastest-growing pillars of modern medicine. By analyzing genetic material to detect mutations, pathogens, and chromosomal abnormalities, DNA-based testing is transforming how diseases are predicted...
Read More...
Jun 30, 2026
Zymeworks Announces Acquisition of Theravance Biopharma; Ipsen to Acquire Kartos Therapeutics; Viridian Therapeutics Wins U.S. FDA Approval for Lumvoa; Replimune Reaches FDA Milestone with RP1 BLA Resubmission Acceptance; Epicrispr Announces Encouraging Clinical Data for EPI-321 in FSHD
Zymeworks Signs Definitive Agreement to Acquire Theravance Biopharma Zymeworks Inc. has signed a definitive agreement to acquire Theravance Biopharma, Inc., marking a strategic step in expanding its commercial portfolio. The acquisition will bring YUPELRI®, the first and only once-daily nebulized long-acting mus...
Read More...
Jun 29, 2026
Ionis’ TRYNGOLZA Approval Raises the Stakes in the Triglyceride-Lowering Race
Summary Over 3 million Americans live with sHTG, including around 1 million high-risk patients with triglycerides ≥880 mg/dL or ≥500 mg/dL plus a history of acute pancreatitis or other comorbidities. In June 2026, the FDA approved Ionis’ TRYNGOLZA (already approved for FCS in 2024) as the first and only trea...
Read More...